

Monique DONTENWILL
UMR 7021 CNRS, University of Strasbourg, Faculty of
Pharmacy, Illkirch, France
Nationality: French
Date of Birth: ///////////////
Place of Birth: ///////////////
Mobile Phone: +33 (0)6//////////
Office Phone : +33 (0)368854267
Email : monique.dontenwill@unistra.fr

EDUCATION

1984 : PhD in Molecular and Cellular Biology, option Neurochemistry, Université Louis Pasteur, Strasbourg I. « Proposition de bases moléculaires pour la reconnaissance interneuronale au moment de la synaptogenèse dans le cervelet de rat » (supervised by Dr JP Zanetta, Centre de Neurochimie du CNRS, UPR416, Strasbourg), awarded the Dina Surdin thesis prize.

2000 : Accreditation to Direct Research (HDR), Université Louis Pasteur, Strasbourg I ; « Le récepteur des imidazolines : de l'hypothèse aux réalités ». (supervised by Pr P Bousquet, Laboratoire de Neurobiologie et Pharmacologie Cardiovasculaire, UPRES JE2104)

PROFESSIONAL CAREER

1986-2001 : from the Molecule to the Therapeutic Target (Cardiovascular field)

Laboratoire de Neurobiologie et Pharmacologie Cardiovasculaire, Faculté de Médecine, Strasbourg (Pr P. Bousquet).

Postdoctoral position (1986-1988) : supported by the Fondation pour la Recherche Médicale.

CNRS CR scientist (1988), DR2 (2006), DR1 (2016).

Head of Molecular and Cellular Biology in a multidisciplinary group (1992 – 2001).

Involved in transdisciplinary projects with chemists, physiologists, clinicians, biologists.

Research fields: Human I1 Imidazoline Receptor characterisation. purification and molecular characterization, characterization of endogenous ligands, signaling pathways, characterization of new specific ligands and associated cellular effects.

Expert in receptor biology, structure/activity relationships, signaling pathways. Involved in the studies of the added value of Rilmenidine (an anti-hypertensive drug) from Laboratoires Servier.

2002- present: from the Therapeutic Target to the Molecule (Oncology field)

Topic and location mobility, Institut Gilbert Laustriat, UMR7175 CNRS, Faculté de Pharmacie, Strasbourg (Prof. C. Kedinger), renamed as UMR7213 CNRS, Faculté de Pharmacie, Strasbourg in 2009 and UMR7021 CNRS in 2018 (Dir Prof. Y. Mély).

Research fields: $\alpha 5\beta 1$ integrin as a biomarker and a therapeutic target in glioblastoma, molecular characterization, exploration of the role of associated protein in the expression and functions of the target; characterization of antagonist effects and search for new integrin specific ligands; *in vitro* and *in vivo* studies of the target and potential new therapies.

Interdisciplinary and translational research in collaborative projects including clinicians and pharmaco-chemists.

2013- present: Team leader (Tumoral signaling and therapeutic targets) and principal investigator (Integrins and cancer) at UMR-CNRS 7021.

2018-present: Deputy-director of the UMR-CNRS 7021.

5 RECENT PUBLICATIONS

1. S SANI, M MESSE, Q FUCHS, M PIERREVELCIN, P LAQUERRIERE, N ENTZ-WERLE, D REITA, N ETIENNE-SELLOUM, V BRUBAN, L CHOULIER, S MARTIN and **M DONTENWILL**. Biological relevance of RGD-integrin subtype-specific ligands in cancer. **2020**, *ChemBioChem*, doi: 10.1002/cbic.202000626

2. FUCHS Q, PIERREVELCIN M, MESSE M, LHERMITTE B, BLANDIN AF, PAPIN C, COCA A, **DONTENWILL M**, ENTZ-WERLE N. Hypoxia Inducible Factors' Signaling in Pediatric High-Grade Gliomas: Role, Modelisation and Innovative Targeted Approaches. **2020**, *Cancers* (Basel). Apr 15;12(4):979. doi: 10.3390/cancers12040979.

3. E HARNOUCH, J SEITLINGER, H CHADDA, J BARTHS L DESAUBRY, S GRANDEMANGE, T MASSFELDER, G

UBEAUD-SEQUIER G FUHRMANN F FIORETTI, S SAIDU, **M DONTENWILL**, N BENKIRANE-JESSEL, Y IDOUX-GILLET
Flavagline synthetic derivative induces senescence in glioblastoma cancer cells without being toxic to healthy astrocytes. **2020**, *Scientific Reports*, Aug 13;10(1):13750. doi: 10.1038/s41598-020-70820-6.

4. FECHTER P., CRUZ DA SILVA E., MERCIER M.-C., NOULET F, ETIENNE-SELOUM N, GUENOT D, LEHMANN M., VAUCHELLES R. MARTIN S. LELONG-REBEL I., RAY A.-M., SEGUIN C., **DONTENWILL M.** & CHOULIER L. RNA aptamers targeting integrin $\alpha 5\beta 1$ as probes for cyto- and histo-fluorescence in glioblastoma. **2019**, *Mol Ther Nucleic Acids.*,17:63-77. doi: 10.1016/j.omtn.2019.05.006.

5. G RENNER, H JANOUSKOVA, F NOULET, V KOENIG, E GUERIN, S BÄR, J NUESCH, F RECHENMACHER, S NEUBAUER, H KESSLER, A-F BLANDIN, L CHOULIER, N ETIENNE-SELLOUM, M LEHMANN, I LELONG-REBEL, S MARTIN AND **M DONTENWILL**. Integrin $\alpha 5\beta 1$ and p53 convergent pathways in the control of anti-apoptotic proteins PEA-15 and survivin in high grade glioma. **2016**, *Cell Death and Differentiation*, doi: 10.1038/cdd.2015.131. Apr;23(4):640-53.

HONORS AND AWARDS

Deputy director of ITI InnoVec

Member of the CoCNRS, INSB, section 28 (since 2016)

Member of the COSC, Cancéropôle Est (since 2018)

Member of the CoPil PAIR tumeurs cérébrales, INCA, (2019-2020)

Member of the Scientific Council of DRCl (Direction de la Recherche Clinique et des Innovations), Hospital of Strasbourg – representative of the Faculty of Pharmacy (since 2016).

Member of the Administrative Council of the Paul Strauss Center (anti-cancer Center of Strasbourg) – representative of INCA (since 2016)

Member of the Scientific Council of the Ligue contre le Cancer Grand Est (2016-2019).

Member of the Administrative council of Association des NeuroOnCologues d'Expression Française (ANOCEF) -

Member of the Nord Est Neuro Oncologists (NENO) association.

Member of the European Association of Cancer Research.

Member of the Scientific and Administrative councils of "Life and Health" Doctoral school, Strasbourg University (2007-2016).

Expert for the Faculty of Pharmacy (sections CNU 85, 86, 87), Strasbourg. Member of examination boards for the selection of assistant professors and professors

Member of PhD and HDR examination boards

Expert for the ANR, Cancéropôle Grand Ouest, the Czech Foundation of Science, the National Polish Science Center, the AICR, Unistra/IDEX, Ligue contre le Cancer GO, MP...

Reviewer for various international pharmacological and biological journals.

Project manager for grants Ligue contre le Cancer (2003-2021), ARC (2009-2010, 2013-2014, 2015-2016, 2017-2018), INCA (2007), Alsace contre le Cancer (2011-2012), Canceropole GE (2013-2014), SATT Conectus (valorisation – 2014). INCA (2018-2021)